Paclitaxel

Generic Name: Paclitaxel

Brand Names: Abraxane, Taxol, Naveruclif, Pazenir, Apexelsin

Drug Type: Small Molecule

Chemical Formula: C_₄₇H_₅₁NO_₁₄

CAS Number: 33069-62-4

Unique Ingredient Identifier: P88XT4IS4D

Background: Paclitaxel is a chemotherapeutic agent marketed under the brand name Taxol among others. Used as a treatment for various cancers, paclitaxel is a mitotic inhibitor that was first isolated in 1971 from the bark of the Pacific yew tree which contains endophytic fungi that synthesize paclitaxel. It is available as an intravenous solution for injection and the n...

Indication: Used in the treatment of Kaposi's sarcoma and cancer of the lung, ovarian, and breast. Abraxane® is specfically indicated for the treatment of metastatic breast cancer and locally advanced or metastatic non-small cell lung cancer.

Associated Conditions: Advanced Cervical Cancer, Advanced Head and Neck Cancer, Advanced Ovarian Cancer, Advanced Soft Tissue Sarcoma, Esophageal Cancer, Fallopian Tube Cancer, Gastric Cancer, Kaposi's Sarcoma, Locally Advanced Non-Small Cell Lung Cancer, Metastatic Bladder Cancer, Metastatic Breast Cancer, Metastatic Melanoma, Metastatic Non-Small Cell Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), Ovarian Cancer, Pancreatic Adenocarcinoma Metastatic, Peritoneal Cancer, Recurrent Small Cell Lung Cancer (SCLC), Advanced Bladder cancer, Advanced Thymoma, Metastatic Penile cancer, Refractory Testicular germ cell cancer

Associated Therapies: -

Clinical Trials

Predicting Peripheral Neuropathy of Paclitaxel for Gastric Cancer

Recruiting

Conditions: Chemotherapy-induced Peripheral Neuropathy
Gastric Cancer
Paclitaxel
Ramucirumab

Interventions: Drug: Paclitaxel

First Posted Date: 2024-07-08

Last Posted Date: 2024-07-08

Lead Sponsor: City of Hope Medical Center

Target Recruit Count: 150

Registration Number: NCT06490159

Locations: 🇯🇵
Kawasaki Medical University, Kurashiki, Okayama, Japan

Predicting the Efficacy in Advanced Gastric Cancer.

Recruiting

Conditions: Chemotherapy Effect
Paclitaxel
Gastric Cancer
Ramucirumab

Interventions: Drug: Paclitaxel

First Posted Date: 2024-07-08

Last Posted Date: 2024-07-08

Lead Sponsor: City of Hope Medical Center

Target Recruit Count: 150

Registration Number: NCT06490055

Locations: 🇯🇵
Kawasaki Medical University, Kurashiki, Okayama, Japan

Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Participants With Endometrial Cancer After Platinum-Based Chemotherapy and Immunotherapy

Phase 3

Recruiting

Conditions: Endometrial Cancer

Interventions: Drug: Doxorubicin
Drug: Sacituzumab govitecan-hziy
Drug: Paclitaxel

First Posted Date: 2024-07-03

Last Posted Date: 2024-12-20

Lead Sponsor: Gilead Sciences

Target Recruit Count: 520

Registration Number: NCT06486441

Locations: 🇯🇵
Mie University Hospital, Mie, Japan
🇯🇵
Hyogo Cancer Center, Hyogo, Japan
🇺🇸
City of Hope, Irvine, California, United States

and more 33 locations

Utility of Adjusting Chemotherapy Dose & Dosing Schedule With the SALVage Weekly Dose-dense Regimen in Patients With Poor Prognostic OVARian Cancers Based on the Tumor Unfavorable Primary Chemosensitivity and Incomplete Debulking Surgery

Phase 3

Recruiting

Conditions: Ovarian Cancer

Interventions: Drug: Carboplatin
Drug: Paclitaxel

First Posted Date: 2024-06-26

Last Posted Date: 2024-11-18

Lead Sponsor: ARCAGY/ GINECO GROUP

Target Recruit Count: 250

Registration Number: NCT06476184

Locations: 🇮🇹
Azienda Ospedaliero-Universitaria Ss.Antonio E Biagio E C.Arrigo Alessandria, Alexandrie, Italy
🇮🇹
Azienda Ospedaliero-Universitaria Di Bologna IRCCS Istituto Di Ricerca E Di Cura A Carattere Scientifico, Bologna, Italy
🇮🇹
Careggi University Hospital, Florence, Italy

and more 54 locations

Sapanisertib and Serabelisib (PIKTOR) With Paclitaxel and a Substudy With Diet in Patients With Advanced/Recurrent Endometrial Cancer

Phase 2

Recruiting

Conditions: Endometrial Cancer

Interventions: Drug: Sapanisertib
Drug: Serabelisib
Drug: Paclitaxel

First Posted Date: 2024-06-17

Last Posted Date: 2024-12-18

Lead Sponsor: Faeth Therapeutics

Target Recruit Count: 40

Registration Number: NCT06463028

Locations: 🇺🇸
Women's Cancer Care Associates, LLC, Albany, New York, United States
🇺🇸
Avera Cancer Institute, Sioux Falls, South Dakota, United States

Safety, Preliminary Effectiveness of BNT327, an Investigational Therapy for Patients With Small-cell Lung Cancer in Combination With Chemotherapy

Phase 2

Recruiting

Conditions: Extensive-stage Small-cell Lung Cancer
Small-cell Lung Cancer

Interventions: Drug: BNT327 Dose Level 1 (DL1)
Drug: BNT327 Dose Level 2 (DL2)
Drug: Etoposide
Drug: Paclitaxel
Drug: Topotecan
Drug: Carboplatin

First Posted Date: 2024-06-07

Last Posted Date: 2024-11-25

Lead Sponsor: BioNTech SE

Target Recruit Count: 110

Registration Number: NCT06449209

Locations: 🇺🇸
Hematology Oncology Associates of Treasure Coast, Port Saint Lucie, Florida, United States
🇺🇸
Tallahassee Memorial Physician Partners - Cancer & Hematology Specialists, Tallahassee, Florida, United States
🇺🇸
Carle Foundation Hospital d/b/a Carle Cancer Center, Urbana, Illinois, United States

and more 39 locations

Safety and Preliminary Effectiveness of BNT327, an Investigational Therapy for Breast Cancer, When Given in Combination With Chemotherapy

Phase 2

Recruiting

Conditions: Locally Advanced Breast Cancer
Triple Negative Breast Cancer
Metastatic Triple Negative Breast Cancers

Interventions: Drug: BNT327 Dose Level 1 (DL1)
Drug: BNT327 Dose Level 1 (DL2)
Drug: Paclitaxel
Drug: Carboplatin
Drug: Eribulin
Drug: Nab-placlitaxel
Drug: BNT327 Optimized Dose
Drug: Gemcitabine
Drug: BNT327 Equivalent Q3W Dose

First Posted Date: 2024-06-07

Last Posted Date: 2024-12-17

Lead Sponsor: BioNTech SE

Target Recruit Count: 70

Registration Number: NCT06449222

Locations: 🇺🇸
Saint John's Health Center - John Wayne Cancer Institute (JWCI), Santa Monica, California, United States
🇺🇸
Carle Foundation Hospital d/b/a Carle Cancer Center, Urbana, Illinois, United States
🇺🇸
Bozeman Health Deaconess Hospital Cancer Center, Bozeman, Montana, United States

and more 32 locations

Substudy 06D: Combination Therapies in Second Line (2L) Gastroesophageal Adenocarcinoma (MK-3475-06D/Keymaker-U06)

Phase 1

Recruiting

Conditions: Gastroesophageal Adenocarcinoma
Esophageal Neoplasms
Gastroesophageal Junction
Esophageal Cancer

Interventions: Biological: Ramucirumab
Biological: MK-2870
Drug: Paclitaxel

First Posted Date: 2024-06-06

Last Posted Date: 2024-12-06

Lead Sponsor: Merck Sharp & Dohme LLC

Target Recruit Count: 90

Registration Number: NCT06445972

Locations: 🇧🇷
Liga Norte Riograndense Contra o Câncer ( Site 8303), Natal, Rio Grande Do Norte, Brazil
🇺🇸
University of Arizona Cancer Center-University of Arizona Cancer Center ( Site 8927), Tucson, Arizona, United States
🇺🇸
Norton Cancer Institute - Downtown ( Site 8900), Louisville, Kentucky, United States

and more 19 locations